Skip to content
S8040Senate2023-2024 SessionSame asA8502

Cover Biomarker Medical Testing

Official title

“Requires health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes”

Sponsor Roxanne J. PersaudSD-19
Status
Senate Floor Calendar
Impact
8/10
Significant
Outcome
Companion signed

Bill progress

Signed via A8502

What's happening

This bill requires health insurance and Medicaid in New York to cover biomarker precision medical testing for diagnosis, treatment, or management of diseases, and expands the criteria and sources for coverage approval.

Why it matters

  1. Broader Approval Criteria. The bill expands the sources that can justify coverage of biomarker precision medical tests—including not just FDA approvals and Medicare policies, but also peer-reviewed scientific literature and a wider range of clinical practice guidelines. This means more tests could be covered, allowing faster adoption of new, evidence-supported diagnostics.

  2. More Inclusive Definitions. By updating and broadening the definitions of "biomarker" and "biomarker precision medical testing," the legislation ensures that a wider array of advanced and emerging testing methods (including multiplex panels and non-traditional biomarkers) will be eligible for coverage.

  3. Patient-Centered Implementation. The law requires that coverage be provided in a way that minimizes disruptions to care, such as reducing the need for multiple biopsies or samples. This could lead to less invasive, more streamlined testing experiences for patients.

  4. Delayed Start Date. The effective date for these expanded coverage requirements is moved from April 1, 2024 to January 1, 2025, giving insurers, Medicaid, and providers more time to prepare for these changes—potentially smoothing the transition for both patients and the healthcare system.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Health insurers

    The bill would revise biomarker testing coverage criteria, remove a specific coverage-exception process requirement and delay the mandate’s effective date to January 1, 2025.

  • Medicaid recipients

    The bill would require coverage of biomarker precision medical testing supported by specified evidence sources, including qualifying peer-reviewed studies, while removing a specific process for requesting coverage exceptions.

  • Watching

    Prescribing clinicians

    The bill would change the evidence standards for covered testing used to diagnose, treat or manage disease or guide treatment decisions through ongoing monitoring.

  • In-network laboratory facilities

    The coverage definition would include single-analyte and multiplex panel tests performed at participating laboratories that meet the bill’s CLIA certification or waiver requirements.

Headline styles

Cover Biomarker Medical Testing

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Roxanne J. Persaud

Senator · Senate District 19

Chair, Social Services

No co-sponsors yet.

History

  1. Substituted by A8502
  2. Ordered to third reading cal.40
  3. Referred to rules

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A8502Assembly

Cover Biomarker Medical Testing

Signed by Governor · Sponsor Pamela J. Hunter

Impact 8 · SignificantSigned into law

Full text

6 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8040

IN SENATE

January 5, 2024

Introduced by Sen. PERSAUD -- read twice and ordered printed, and when printed to be committed to the Committee on Rules

AN ACT to amend the insurance law and the social services law, in relation to requiring health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes; and to amend a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, in relation to the effectiveness thereof

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 11-c of subsection (i) of section 3216 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(11-c) (A) Every policy which provides medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of a covered person's] to guide treatment decisions for, an insured's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for an insured's disease or condition:

(i) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02625-08-4

(ii) centers for medicare and medicaid services national coverage determinations [and] or medicare administrative contractor local coverage determinations; [or]

(iii) nationally recognized clinical practice guidelines [such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.]; or

(iv) peer-reviewed literature and peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.

(B) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(C) [The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this paragraph. Such process shall be made readily accessible on the website of the insurer.

(D)] As used in this paragraph, the following terms shall have the following meanings:

(i) "Biomarker" means a [defined] characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. [Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.]

(ii) "Biomarker precision medical testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multi-plex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(iii) ["Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(iv)] "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 2. Paragraph 11-c of subsection (l) of section 3221 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(11-c) (A) Every insurer delivering a group or blanket policy or issuing a group or blanket policy for delivery in this state that provides coverage for medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of a covered person's] to guide treatment decisions for, an insured's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for an insured's disease or condition:

(i) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(ii) centers for medicare and medicaid services national coverage determinations [and] or medicare administrative contractor local coverage determinations; [or]

(iii) nationally recognized clinical practice guidelines [including, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.]; or

(iv) peer-reviewed literature and peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.

(B) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(C) [The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this paragraph. Such process shall be made readily accessible on the website of the insurer.

(D)] As used in this paragraph, the following terms shall have the following meanings:

(i) "Biomarker" means a [defined] characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. [Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.]

(ii) "Biomarker precision medical testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multi-plex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(iii) ["Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(iv)] "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 3. Subsection (p-1) of section 4303 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(p-1) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation that provides coverage for medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of a covered person's] to guide treatment decisions for, an insured's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for an insured's disease or condition:

(A) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(B) centers for medicare and medicaid services national coverage determinations [and] or medicare administrative contractor local coverage determinations; [or]

(C) nationally recognized clinical practice guidelines [such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.]; or

(D) peer-reviewed literature and peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.

(2) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(3) [The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this subsection. Such process shall be made readily accessible on the website of the insurer.

(4)] As used in this subsection, the following terms shall have the following meanings:

(A) "Biomarker" means a [defined] characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. [Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.]

(B) "Biomarker precision medical testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multi-plex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(C) ["Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(D)] "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 4. Paragraph (mm) of subdivision 2 of section 365-a of the social services law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(mm) (i) biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of] to guide treatment decisions for, a recipient's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for a recipient's disease or condition:

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the social services law, in relation to requiring health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes; and to amend a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medi- caid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, in relation to the effectiveness thereof

Purpose

This is a chapter amendment that makes changes to provisions of L.2023, c.754, to require commercial insurance policies and Medicaid to cover biomarker testing

Summary of provisions

This legislation makes technical changes, allows coverage for biomarker testing if additional conditions are met, and changes the effective date of the underlying chapter.

Justification

This legislation is a negotiated change to the underlying chapter.

Legislative history

Chapter Amendment to Chapter 754 of the Laws of 2023. S.1196A and A.1673A both passed the Senate and Assembly in June 2023.

Fiscal implications

None

Effective date

This act shall take effect immediately; provided however that sections one, two, three and four of this act shall take effect on the same date and in the same manner as a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S.1196-A and A.1673-A, takes effect.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.